CFDE Data Portal | Search B3GALT5

	Label	Description
	B3GALT5 Gene (Entity type)	ENSG00000183778 - beta-1,3-galactosyltransferase 5
	B3GALT5 associations Collection (Entity type)	Associations for B3GALT5_associations
	B3GALT5 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	B3GALT5-AS1 Gene (Entity type)	ENSG00000184809 - B3GALT5 antisense RNA 1
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

B3GALT5

ENSG00000183778 - beta-1,3-galactosyltransferase 5

B3GALT5 associations

Associations for B3GALT5_associations

B3GALT5 associations.tsv

A file from IDG as part of the Harmonizome project

B3GALT5-AS1

ENSG00000184809 - B3GALT5 antisense RNA 1

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

A Gene Set from LINCS

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE139987 1 V 0 ROSIGLITAZONE MOUSE DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.